Business● Low32m ago · Nov 10, 2026, 7:31 PM
PepGen climbs 100% as BofA upgrades on new mid-stage trial data for lead asset
GlobeAlert Desk · curated from Seeking Alpha Tech · global
PepGen's stock has increased by 100% following an upgrade by BofA, attributed to new mid-stage trial data for its primary product. This indicates a significant positive market reaction to the company's latest research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business31m agoNvidia hires law firm Wachtell Lipton and former US prosecutor to investigate CEO probeSeeking Alpha TechBusiness32m agoFreightCar America reaffirms 2026 adjusted EBITDA of $15M-$19M as aftermarket revenue rises 65%Seeking Alpha TechBusiness32m agoAutolus expects full-year 2026 AUCATZYL net product revenue at or above $150M, as BOBCAT data shifts to October 2027Seeking Alpha TechBusiness32m agoRanger targets 24 contracted ECHO rigs by end of 2027 while expecting >$10M of 2027 adjusted EBITDA from STEP coiled tubing assetsSeeking Alpha Tech